Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125554261 | 12555426 | 1 | I | 20160712 | 20160714 | 20160714 | PER | US-009507513-1607USA005250 | MERCK | 0.00 | Y | 0.00000 | 20160714 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125554261 | 12555426 | 1 | PS | NUVARING | ETHINYL ESTRADIOLETONOGESTREL | 1 | Vaginal | THE RING MUST REMAIN IN PLACE CONTINUOUSLY FOR THREE WEEKS FOLLOWED BY A ONE-WEEK RING-FREE INTERVAL | 21187 | VAGINAL RING | /month |
Indications of drugs used
no results found |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125554261 | 12555426 | Device breakage | |
125554261 | 12555426 | No adverse event |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |